Helena Yu, MD

Research Project:
Developing a Model to Select Patients for Radiation Therapy in EGFR+ Lung Cancer

Grant Awarded:

Lung Cancer Discovery Award

Research Topics:

biomarkers
clinical research
imaging radiology
modeling

Research Disease:

lung cancer

Lung cancer with genetic changes in the epidermal growth factor receptor (EGFR) protein occurs in up to 20% of all lung cancers. Osimertinib is a targeted therapy tailored for these cancers. The treatment is initially effective, but lung cancer eventually adapts and regrows. No subsequent oral targeted therapies are available. Some patients have excellent responses to osimertinib but have a few areas where the cancer has remains. We found that radiation therapy can treat these lesions, extending disease control with osimertinib. However, there are no guidelines for selecting patients for radiation therapy, a treatment that has potentially serious side effects. With our unique access to patients and samples, we will use advanced imaging techniques and circulating tumor DNA in the blood to develop a model that accurately predicts response to osimertinib in order to select patients for radiation therapy either at maximum tumor shrinkage or at the time of tumor growth on osimertinib.

The Keith R. Ayres Lung Cancer Discovery Award

Page last updated: October 29, 2025

Join the Patient & Caregiver Network

How to Help People Quit

10 Tips to Protect Yourself from Unhealthy Air

State of the Air Key Findings

Become an Advocate

Join a LUNG FORCE Walk

Double Your Gift

Helena Yu, MD

Your Gift = 2X the Impact

Make a Donation

Become a Lung Health Insider

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA